1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

Abstract

Patients (pts) with aggressive metastatic or locally advanced, non-resectable, grade 1-2 well-differentiated duodeno-pancreatic (WDDP) NETs should receive a combination of systemic chemotherapy until progression. Aggressive disease is defined as progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases.